EMA sees fee income reduced by €8m
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is facing a €8m drop in estimated revenue from industry fees this year as a result of changes to the parameters used to calculate fee income. At the same time, it is facing a constantly growing workload including a rise in the number of initial drug approval applications this year, driven mainly by an increase in orphan drug filings.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.